VivoSim Labs Q2 2026 Results: Net Loss of $475K, Loss Narrows
VivoSim Labs reported a net loss of $1.8 million for the six months ended September 30, 2026, a significant improvement from the $5.4 million loss in the prior year period, primarily due to a $5.0 million milestone payment gain. The company transitioned its business model toward 3D human tissue model testing services following FDA regulatory shifts, while significantly increasing its outstanding share count from 2.9 million to 18.1 million during the period.
- Key figure
- Net loss $475K